[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-hyperaldosteronism-due-to-adrenal-adenoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-hyperaldosteronism-due-to-adrenal-adenoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100500538","unilateral-primary-aldosteronism-mineralocorticoid-antagonists-versus-surgical-treatment-100500538",false,"NCT05797558","Unilateral Primary Aldosteronism, Mineralocorticoid Antagonists Versus Surgical Treatment","Unilateral Primary Aldosteronism, Mineralocorticoid Antagonists Versus Surgical Treatment - A Randomized Controlled Trial","UPA-MEST","Inclusion Criteria:\n\n1. Patients with confirmed unilateral PA\n2. Age 18-70 years\n3. Candidate for surgical treatment\n4. No contraindications for minimally invasive surgery or treatment with MRA\n5. Understands oral and written information and provides oral and written informed consent.\n\nExclusion Criteria:\n\n1. Unwilling or unable to undergo surgery\n2. Unwilling to accept medical treatment for 12 months and not receiving standard treatment (surgery)\n3. Impaired renal function with eGFR \\\u003C45 ml\u002Fmin\u002F1,73m2\n4. P-cortisol \\>138 nmol\u002FL following 1-mg overnight dexamethasone suppression test.","ALL","18 Years","70 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is a prospective randomized controlled trial where quality of life and the effectiveness of treatment will be evaluated in 80 patients with confirmed unilateral primary aldosteronism ,randomly assigned to be either treated surgically with unilateral adrenalectomy or to receive medical treatment with eplerenone.",[28],"Primary Hyperaldosteronism Due to Adrenal Adenoma",[30,31,32,33,34,35,36,37,38],"hyperaldosteronism","primary aldosteronism","lateralized aldosteronism","unilateral aldosteronism","eplerenone","spironolactone","randomized trial","quality of life","PASO outcomes","RECRUITING","2025-04-03",{"date":42,"type":43},"2025-04-06","ACTUAL",{"date":45,"type":43},"2023-04-28",{"date":47,"type":22},"2028-05-28",{"name":49,"class":50},"Göteborg University","OTHER",3]